Injectable PrEP, the game changer for HIV prevention?
Dr. Hosseinipour is the Scientific Director of the UNC Project in Lilongwe Malawi and Professor of Medicine at the University of North Carolina at Chapel Hill School of Medicine. Trained in internal medicine, infectious diseases and epidemiology, she has been engaged in HIV Treatment and Prevention clinical trials since 2001. Most recently, she has served as the co-Chair for the HPTN 084, a prevention study comparing injectable Cabotegravir to oral Truvada among cis-gender women. She also directs several research capacity building programs in Malawi, primarily focused on implementation science.